Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 55.3 CHF 0.55%
Market Cap: 970m CHF
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

COPN Price Targets Summary
Cosmo Pharmaceuticals NV

Wall Street analysts forecast COPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for COPN is 99.71 CHF with a low forecast of 79.79 CHF and a high forecast of 139.65 CHF.

COPN Lowest Forecast
Wall Street Target
79.79 CHF
44% Upside
COPN Average Forecast
Wall Street Target
99.71 CHF
80% Upside
COPN Highest Forecast
Wall Street Target
139.65 CHF
153% Upside
Lowest
Price Target
79.79 CHF
44% Upside
Average
Price Target
99.71 CHF
80% Upside
Highest
Price Target
139.65 CHF
153% Upside
Cosmo Pharmaceuticals NV Competitors:
Price Targets
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
35% Upside
4746
Formosa Laboratories Inc
65% Upside
CIPLA
Cipla Ltd
13% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
8% Upside
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
35% Upside
4746
Formosa Laboratories Inc
65% Upside
CIPLA
Cipla Ltd
13% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
8% Upside
J
216080
Jetema Co Ltd
75% Upside
AZN
AstraZeneca PLC
29% Upside
300725
PharmaBlock Sciences Nanjing Inc
21% Upside

Revenue
Forecast

Revenue Estimate
Cosmo Pharmaceuticals NV

For the last 8 years the compound annual growth rate for Cosmo Pharmaceuticals NV's revenue is 19%. The projected CAGR for the next 3 years is -19%.

19%
Past Growth
-19%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cosmo Pharmaceuticals NV

For the last 8 years the compound annual growth rate for Cosmo Pharmaceuticals NV's operating income is 25%. The projected CAGR for the next 3 years is -28%.

25%
Past Growth
-28%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cosmo Pharmaceuticals NV

For the last 8 years the compound annual growth rate for Cosmo Pharmaceuticals NV's net income is 27%. The projected CAGR for the next 3 years is -27%.

27%
Past Growth
-27%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
COPN intrinsic value, competitors valuation, and company profile.
DCF Valuation
COPN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
COPN stock valuation using valuation multiples.
Wall Street Estimates
COPN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
COPN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is COPN's stock price target?
Price Target
99.71 CHF

According to Wall Street analysts, the average 1-year price target for COPN is 99.71 CHF with a low forecast of 79.79 CHF and a high forecast of 139.65 CHF.

What is Cosmo Pharmaceuticals NV's Revenue forecast?
Projected CAGR
-19%

For the last 8 years the compound annual growth rate for Cosmo Pharmaceuticals NV's revenue is 19%. The projected CAGR for the next 3 years is -19%.

What is Cosmo Pharmaceuticals NV's Operating Income forecast?
Projected CAGR
-28%

For the last 8 years the compound annual growth rate for Cosmo Pharmaceuticals NV's operating income is 25%. The projected CAGR for the next 3 years is -28%.

What is Cosmo Pharmaceuticals NV's Net Income forecast?
Projected CAGR
-27%

For the last 8 years the compound annual growth rate for Cosmo Pharmaceuticals NV's net income is 27%. The projected CAGR for the next 3 years is -27%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.